Dosage Forms Designed to Deliver
At Upperton, we have extensive experience taking research projects from early proof of concept and feasibility through scale up and onto clinical manufacture for a range of common dosage forms. Our team can manage the complexity of your project with a creative application of science, knowledge and experience to help you find the best solution to take your project to first-in-human (FIH) studies and beyond. We’re flexible, fast and affordable; with the ability to start a project within 2 to 4 weeks.
As a business we focus our development and clinical manufacturing areas in three delivery routes; these being Oral, Pulmonary and Nasal Delivery
Using our science led approach, and working closely with the client at all stages, we start the development process by defining the project aims and understanding your target product profile.
Early on, we undertake pre-formulation activities, including characterising the active ingredient. Our experienced formulators then select excipients to develop the target dosage form. At all stages, we consider the suitability of the formulation, process for scale-up and ultimate commercialisation. Stability studies are a fundamental component of development work, with extensive analytical techniques available to characterise produced powders and dosage forms.
Once a suitable formulation has been developed, we will work to get the process to the target scale in our pilot plant which contains equipment that mirrors our GMP facility; providing confidence in the process before committing to clinical manufacture.
Contact us to find out more how we can support your formulation development requirements.
Upperton’s formulation development team will confidently guide you on the best route forward.
Utilise our expertise and know-how to solve problems unique to your challenging molecule.
FIH through to phase II clinical
manufacturing. No project is too small or too challenging.